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ABSTRACT
The MUS81 complex is crucial for preserving genome
stability through the resolution of branched DNA
intermediates in mitosis. However, untimely activa-
tion of the MUS81 complex in S-phase is danger-
ous. Little is known about the regulation of the hu-
man MUS81 complex and how deregulated activa-
tion affects chromosome integrity. Here, we show
that the CK2 kinase phosphorylates MUS81 at Ser-
ine 87 in late-G2/mitosis, and upon mild replication
stress. Phosphorylated MUS81 interacts with SLX4,
and this association promotes the function of the
MUS81 complex. In line with a role in mitosis, phos-
phorylation at Serine 87 is suppressed in S-phase
and is mainly detected in the MUS81 molecules as-
sociated with EME1. Loss of CK2-dependent MUS81
phosphorylation contributes modestly to chromo-
some integrity, however, expression of the phospho-
mimic form induces DSBs accumulation in S-phase,
because of unscheduled targeting of HJ-like DNA
intermediates, and generates a wide chromosome
instability phenotype. Collectively, our findings de-
scribe a novel regulatory mechanism controlling the
MUS81 complex function in human cells. Further-
more, they indicate that, genome stability depends
mainly on the ability of cells to counteract target-
ing of branched intermediates by the MUS81/EME1
complex in S-phase, rather than on a correct MUS81
function in mitosis.
INTRODUCTION
Resolution of branched DNA intermediates formed dur-
ing recombination or upon replication stress is impor-
tant for cell cycle progression and genome stability main-
tenance (1,2). Consistently, cells have evolved multi-
ple and redundant mechanisms to ensure processing of
recombination/replication intermediates, minimizing the
risk of entering into mitosis and performing cell division
with unreplicated or untangled chromosomes (3).
In eukaryotes, the Mus81/Mms4EME1 heterodimer, the
Mus81 complex, is the major endonuclease involved in
the resolution of recombination or replication DNA in-
termediates (4–6). The main physiological function of the
Mus81 complex is performed during the G2/M phase of
the cell cycle (1). However, recent evidence clearly show
activation of the Mus81 complex also in S-phase under
conditions of persisting replication stress (7–10). Interest-
ingly, such ‘pathological’ Mus81-dependent processing of
replication intermediates would be essential for prolifera-
tion, but it is also involved in the generation of chromo-
some instability (7,11–13). Hence, as unscheduled activa-
tion of endonucleolytic cleavage is detrimental for genome
integrity, Mus81 complex activity needs to be tightly regu-
lated. In yeast, regulation of the Mus81 complex is largely
dependent on phosphorylation of the non-catalytic sub-
unitMms4 by themitotic kinases Cdc28CDK1 andCdc5PLK1
(4,14). Adding further complexity to the mechanism, acti-
vation of Mus81/Mms4 in mitosis has been recently shown
to require Cdc7-Dbf4, another cell cycle-regulated kinase
(15). In fission yeast, Mus81/Eme1 function is also pos-
itively controlled by Cdc2CDK1 and Chk1 in response to
DNA damage while it is repressed by the checkpoint ki-
nase Cds1CHK2, in S-phase (16,17). Although evidence sug-
gest that mitotic kinases may regulate the function of the
MUS81 complex in human cells too, we do not have much
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mechanistic insights. The recent observation of the crucial
role of CDK1-mediated phosphorylation of SLX4 in con-
trollingMUS81 complex function does providemechanistic
clues, but also make difficult to distinguish between direct
vs. indirect effects of CDK1 on MUS81-dependent resolu-
tion (18,19). Moreover, although signs of phosphorylation-
induced changes in the electrophoretic mobility of EME1
and EME2 are apparent (20), little if any information exist
on phosphorylation of the MUS81 subunit and its possible
functional relevance. However, phosphorylation of the in-
variant subunit of the two MUS81/EME complexes could
be a more efficient way to regulate activity of the holoen-
zyme, as well as association with proteins that can influence
its biological activity under normal or pathological con-
ditions (1,7,20,21). Hence, it is likely that the MUS81 un-
dergoes cell-cycle-specific phosphorylation events that may
contribute to tightly regulate its function together with the
observed modification of the EME1/2 subunit.
In addition to PLK1 and CDK1, an attractive kinase for
the regulation of MUS81 complex is the pleiotropic CK2
(22,23). Indeed, CK2 is important to regulate mitotic pro-
gression, is activated by CDK1 and phosphorylates several
repair/recombination enzymes, such as MDC1, MRE11
and RAD51 (22,24–27).
Here, we found that CK2 phosphorylates the N-terminal
region of MUS81 at Serine 87 (S87) in the early mitotic
stage and after mild replication stress. Phosphorylation by
CK2 stimulates MUS81/EME1 association with SLX4,
and it is required for the biological function of the com-
plex in mitosis. Introduction of a phosphomimetic muta-
tion at S87 results in unscheduled function of MUS81 com-
plex during DNA replication and accumulation of exten-
sive genome instability already in untreated cells. There-
fore, our results represent the first demonstration of regula-
tory phosphorylation of theMUS81 subunit of theMUS81
complex in human cells, which is specifically targeted at the
MUS81/EME1 heterodimer and is crucial for its function
during mitosis. As CK2 is upregulated in many tumours,
deregulation of this mechanism may contribute to increase
their genomic instability during cancer development.
MATERIALS AND METHODS
In vitro kinase assay
For in vitro kinase assays, 300 ng or 2g (MS/MS) of the in-
dicated GST-fused MUS81 fragments were incubated with
recombinant purified CK2 (NEB), kinase in the presence
of 32P-ATP, or ATP, and in kinase-specific reaction buffer
prepared according to the manufacturers’ directions. After
washing, GST-fragments were released and analysed as pre-
viously reported (28). Caseins (Sigma-Aldrich) were used as
positive control in the CK2 kinase assay. For the full-length
assay, 200 ng of full-lenght MUS81 immunopurified from
HEK293T cells (Origene) was incubated with 200 ng of
CK2 kinase. Phosphorylation was analysed by SDS-PAGE
and WB.
Cell culture, generation of cell lines and RNA interference
MRC5SV40 and HEK293T cell lines were maintained as
described (28).
To obtain the MRC5shMUS81 cells or the shMUS81-
HEK293T cells, a retroviral plasmid containing anMUS81-
targeting shRNA sequence (Origene cod. TR303095, se-
quence #1) was nucleofected using the Neon system (Life
technologies). Three days after nucleofection, cells were
subjected to selection with 500 ng/ml puromycin and
resistant clones expanded, tested for MUS81 depletion
and phenotype before further use. To complement MRC5
shMUS81 cells with the wild-type MUS81 or its phos-
phomutants, the wild type form of MUS81 ORF cloned
into the pCMV-Tag2B plasmid was subjected to SDM
(Quickchange II XL – Stratagene) to introduce the S87A
or S87D mutations.
After the first round of mutagenesis, all MUS81 ORFs
were made RNAi-resistant by SDM, sequence-verified and
cloned into pEF1a-IRES-NEO vector by the Gibson As-
sembly protocol (NEB). Sequence-verified plasmids were
then transfected into MRC5 shMUS81 cells by the Neon
nucleofector (Life technologies) in order to obtain cell
lines stably expressing MUS81 and its mutant forms. Cell
colonies were selected by 1 mg/ml G418 antibiotic (Santa
Cruz Biotechnologies). RNA interference against MUS81
was performed as previously reported (11). In all ex-
periments, cells were transfected using Lullaby (OZ Bio-
sciences). RNA interference against EME2 was performed
with siRNA-SMART pool, 10 nmol (197342) from Dhar-
macon. The efficiency of protein depletion was monitored
by western blotting 72 h after transfection. Cell lines de-
rived from MRC5SV40 human fibroblasts that have been
stably depleted of endogenous MUS81 using shMUS81-
expressing lentiviruses and their isogenic counterpart that
stably expresses wild-type MUS81 or each one of the phos-
phorylation mutants have been used in all the experiment
but in the analysis of phosphorylation and enzymatic as-
says. HEK293T cells transiently transfected with plasmids
expressing each of the MUS81 mutant have been used for
in cellulo phosphorylation experiments and for enzymatic
assays.
Chemicals
Hydroxyurea (Sigma-Aldrich) was used at 2 mM, the DNA
replication inhibitor aphidicolin (APH) (Sigma-Aldrich)
was used at 0.2 M (low dose) or 1.5 M (interme-
diate dose). The CK2 inhibitor CX4925 (Selleck chem-
icals) was used at 25 M, the CDK1 inhibitor (RO-
3306, Sigma-Aldrich) at 9 M and WEE1 inhibitor (MK-
1775, Selleck chemicals) was used at 500 M. Nocoda-
zole (Sigma-Aldrich) was used at 0.5 g/l and Thymi-
dine (Sigma-Aldrich) at 2 mM. 5-Bromo-2′-Deoxyuridine
(BrdU, Sigma-Aldrich) was used at 30 M.
Neutral comet assay
Neutral Comet assay was performed as previously de-
scribed (28). A minimum of 200 cells was analyzed for each
experimental point.
Immunoprecipitation and Western blot analysis
Cell lysates and immunoprecipitation experiments were per-
formed as previously described (29). FLAG-tagged proteins
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were immunoprecipitated with anti-FLAG M2 Agarose
Beads (Sigma-Aldrich) while cMYC-tagged proteins were
purified with Myc-TRAP MA magnetic agarose beads
(Chromotek). Western blot was performed using standard
methods. Blots were developed using Westernbright ECL
(Advasta) according to the manufacturer’s instructions.
Quantification was performed on scanned images of blots
using Image Lab software.
PLA (proximity-ligation assay)
The in-situ proximity-ligation assay (PLA; mouse/rabbit
red starter Duolink kit from Sigma-Aldrich) was used as
indicated by the manufacturer. Images were acquired with
Eclipse 80i Nikon Fluorescence Microscope, equipped with
a VideoConfocal (ViCo) system. For each point, at least 500
nuclei were examined and foci were scored at 40×. Paral-
lel samples incubated with only one primary antibody con-
firmed that the observed fluorescence was not attributable
to artefacts. Only nuclei showing more than four bright foci
were counted as positive.
Antibodies
The primary antibodies used were: anti-MUS81 (1:1000;
Santa Cruz Biotechnologies), anti-DDK (Flag Origene,
WB 1:1000, IF 1:200), anti-cMYC (1:1000; Abcam), anti-
CK2 (1:1000; Cell Signaling Technologies), anti-RxxpS/T
(1:1000; Cell Signaling Technologies), anti-SLX4 (WB
1:1000, IF 1:200, Novus biologicals), anti-pS10H3 (1:1000,
Santa Cruz Biotechnologies), anti-H3 (1:1000, Santa Cruz
Biotechnologies), anti-EME1 (1:1000, Santa Cruz Biotech-
nologies), anti-EME2 (1:500, Invitrogen), anti-Cyclin A
(WB: 1:1000, IF: 1:100, Santa Cruz Biotechnologies), anti
53BP1 (1:400, Millipore), anti-BrdU (1:50, Becton Dickin-
son), anti-pS139H2A.X (1:1000,Millipore), anti- -Tubulin
(1:200, Sigma-Aldrich), anti-pS87MUS81 (WB 1:1000, IF
1:200, Abgent) and anti-Lamin B1 (1:10 000; Abcam).
HRP-conjugated matched secondary antibodies were from
Jackson Immunoresearch and were used at 1:40 000.
Chromatin fractionation
Cells (4 × 106 cells/ml) were resuspended in buffer A (10
mM HEPES, [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34
M sucrose, 10% glycerol, 1 mM DTT, 50 mM sodium fluo-
ride, protease inhibitors [Roche]). Triton X-100 (0.1%) was
added, and the cells were incubated for 5 min on ice. Nu-
clei were collected in pellet by low-speed centrifugation (4
min, 1300 × g, 4◦C) and washed once in buffer A. Nuclei
were then lysed in buffer B (3 mM EDTA, 0.2 mM EGTA,
1 mM DTT, protease inhibitors). Insoluble chromatin was
collected by centrifugation (4 min, 1700 × g, 4◦C), washed
once in buffer B + 50 mMNaCl, and centrifuged again un-
der the same conditions. The final chromatin pellet was re-
suspended in 2× Laemmli buffer and sonicated for 15 s in a
Tekmar CV26 sonicator using a microtip at 25% amplitude.
Immunofluorescence
Immunofluorescence microscopy was performed on cells
grown on cover- slips as described previously (28).
Nocodazole-treated cells were blocked and fixwith PTEMF
buffer (30). After blocking, coverslips were incubated for
1hatRTwith the indicated antibodies. For detection of anti-
BrdU, after permeabilization with 0,4%Triton-X 100/PBS,
cells were denatured in HCl 2.5N for 45 min at RT. Alexa
Fluor® 488 conjugated-goat anti mouse andAlexa Fluor®
594 conjugated-goat anti-rabbit secondary antibodies (Life
Technologies) were used at 1:200. Nuclei were stained with
4′,6-diamidino-2-phenylindole (DAPI 1:4000, Serva). Cov-
erslips were observed at 40× objective with the Eclipse 80i
Nikon Fluorescence Microscope, equipped with a Video-
Confocal (ViCo) system. Images were processed by using
Photoshop (Adobe) program to adjust contrast and bright-
ness. For each time point at least 200 nuclei were examined.
Parallel samples incubated with either the appropriate nor-
mal serum or only with the secondary antibody confirmed
that the observed fluorescence pattern was not attributable
to artefacts.
Experiments for labeling cellular DNA with EdU (5-
ethynyl-2′-deoxyuridine). EdUwas added to the cultureme-
dia (10 M), for 30 min. Detection of EdU was performed
used Click-iT EdU imaging Kits (Invitrogen).
Cell cycle analysis by flow cytometry
Cells were processed for flow cytometry as follows: for each
point, 106 cells were collected, and after two washes in
PBS, fixed in 70% cold ethanol. Then, cells were washed in
PBS/BSA 1% and then resuspended in 0.5 g/ml propid-
ium iodide and 0.1mg/mlRNase before analysis. Datawere
analysed with CellQuest and ModFit LT 4.1. software.
Bivariate flow cytometry was performed for anti-BrdU
and anti- -H2AX staining as indicated in the Anti-BrdU
data-sheet (Becton Dickinson).
Growth curve
The cells were seeded at 1.8 × 104 cells per plate. After
trypsinization, cells were counted through electronic count-
ing cells (BioRad) for the following 6 days. The growth curve
of the cell cultures was expressed as number of cells as a
function of time.
Chromosomal aberrations
Cells for metaphase preparations were collected according
to standard procedure and as previously reported (31). Cell
suspension was dropped onto cold, wet slides to make chro-
mosome preparations. The slides were air dried overnight,
then for each condition of treatment, the number of breaks
and gaps was observed on Giemsa-stained metaphases. For
each time point, at least 50 chromosomes were examined
by two independent investigators and chromosomal dam-
age was scored at 100× magnification with an Olympus flu-
orescence microscope.
Statistical analysis
All the data are presented as means of at least three inde-
pendent experiments. Statistical comparisons were made by
Student’s t test or by Anova, as indicated. P < 0.5 was con-
sidered significant.
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Table 1. Putative phosphorylation sites identified in the N-terminal MUS81 region
Kinase Residue Sequence Score Cut-off
CK2 S87 RLQRHRTSGGDHAPD 4,938 3,923
S95 GGDHAPDSPSGENSP 4,819 3,923
S97 DHAPDSPSGENSPAP 4,65 3,923
T159 PNGHHFLTKEELLQR 5,231 3,923
CDKs S95 GGDHAPDSPSGENSP 4,475 1,649
S101 DSPSGENSPAPQGRL 4,205 1,649
PLK1 S101 DSPSGENSPAPQGRL 3,571 3,462
S115 LAEVQDSSMPVPAQP 3,578 3,462
RESULTS
MUS81 is phosphorylated at Serine 87 by the protein kinase
CK2 both in vitro and in vivo
The human MUS81 contains an N-terminal unstructured
region and a HhH domain that are essential to associate
with SLX4, a crucial step for the biological function of
the complex in mitosis (32). Hence, seeking for regulatory
events modulating the MUS81 complex, we scanned the N-
terminal sequence of MUS81 comprising amino acids 1–
200, which includes the SLX4 binding region, for the pres-
ence of putative phosphorylation sites of mitotic kinases.
As shown in Table 1, bioinformatics analysis retrieved sev-
eral CDKs, PLK1 and CK2 putative phosphorylation sites
that score over the specificity threshold of the software. As
CK2 was not previously associated to MUS81 regulation
and its pharmacological inhibition interfered with the for-
mation ofMUS81-dependent DSBs in checkpoint-deficient
cells (7,33) (Supplementary Figure S1), we decided to focus
on this kinase. Hence, to test whether CK2 could phospho-
rylate MUS81 in vitro, we performed a radioactive kinase
assay. As substrates, we used two different fragments com-
prising residues 1–206 or 76–206 of MUS81, fused to GST
and purified from bacteria (Figure 1A). Our kinase assays
showed that CK2 efficiently phosphorylates the N-terminal
MUS81 fragments (Figure 1B).
To confirm phosphorylation and identify phospho-
residues, we incubated the fragment 76–206 ofMUS81 with
recombinant CK2 and analysed the product of the reaction
byMS/MSafter affinity-purification of the phosphorylated
peptides. From the CK2-modified fragment, we identified
three different peptides containing phosphorylated residues
(Figure 1C). Among the three identified residues, S87 was
the most promising because it is very close to the SLX4-
interacting region of MUS81 (34). Hence, to functionally
characterize this phosphorylation event, we generated a
phosphospecific antibody that recognizes the MUS81 pro-
teinmodified at S87. Dot blot assay confirmed that the anti-
pS87MUS81 antibody efficiently recognizes the modified
peptide or the peptide incubated with recombinant CK2,
while it showed no antibody reaction with the peptide in-
cubated with recombinant PLK1 (Supplementary Figure
S2A). Phosphorylation of MUS81 was also confirmed us-
ing a commercial phosphomotif antibody that recognizes
a sequence (RXXpS/T) very similar to that surrounding
S87 (RHRTpS) (Supplementary Figure S2 B). Finally, co-
immunoprecipitation experiments revealed interaction be-
tween the catalytic subunit of the CK2 holoenzyme, CK2,
and MUS81, supporting the possible physiological rele-
vance of S87 modification (Supplementary Figure S2C).
Next, we performed in vivo experiments to test the ability
of the anti-pS87MUS81 antibody to detect MUS81 phos-
phorylation. To this aim, HEK293T cells stably expressing
a shRNA sequence against MUS81 (HEK293TshMUS81)
were transiently transfected with empty vector or with
plasmids expressing the wild-type, the unphosphorylable
(S87A) or the phosphomimetic (S87D) FLAG-tagged
RNAi-resistant form of MUS81 protein. After anti-FLAG
immunoprecipitation, the presence of MUS81 phospho-
rylation was analysed by western blotting. As shown in
Supplementary Figure S3A and S87 phosphorylation was
detected only in the wild-type protein, confirming S87
modification in vivo and the specificity of the antibody.
This result was further corroborated by immunofluores-
cence in MRC5SV40 cells stably expressing the shMUS81
construct (shMUS81), and shMUS81 cells complemented
with the FLAG-tagged-RNAi-resistant form of wild-type
MUS81 or each of the two phosphorylation mutants and
enriched in mitosis using nocodazole (Supplementary Fig-
ure S3B). Our analysis revealed the presence of nuclear
staining in MUS81WT cells, which was not detectable in
shMUS81 cells or in cells expressing the MUS81 mutant
forms (MUS81S87A and MUS81S87D; Supplementary Fig-
ure S3B). Similarly, evaluation of MUS81 S87 phosphory-
lation byWestern blotting in transiently expressing cells en-
riched in M-phase by nocodazole treatment confirmed that
the anti-pS87 antibody efficiently recognised the MUS81
wild-type but not the phosphorylation mutant forms (Sup-
plementary Figure S3C). Interestingly, pharmacological in-
hibition of CK2 substantially reduced S87 phosphoryla-
tion as evaluated by IP/WB or immunofluorescence anal-
ysis (Supplementary Figure S4A and B), proving that S87
residue of MUS81 is an in vivo substrate of the protein ki-
nase CK2.
Altogether, our findings show thatMUS81 is phosphory-
lated by CK2 on S87 both in vitro and in vivo, and that S87
phosphorylation is already detectable during unperturbed
cell growth.
CK2-mediated phosphorylation of MUS81 at Serine 87 is an
early mitotic event stimulated by mild replication stress and
restrained in the MUS81/EME2 complex
It is still poorly defined whether each of the two
MUS81/EMEs complexes shows any cell-cycle specificity
(4,18,20,35). Hence, we analysed if modification by CK2
was cell cycle-dependent. To this aim, HEK293TshMUS81
cells, transiently expressing the wild-type form of MUS81,
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Figure 1. CK2 phosphorylates MUS81 in vitro. (A) Schematic representation of the N-terminal MUS81 fragments. (B) GST-fused N-terminal MUS81
fragments purified from bacteria were incubated with recombinant CK2 and subjected to in vitro radioactive kinase assay. Caseins were used as positive
control. Red boxes indicate position of the fragments. Parenthesis indicates N1-MUS81 degradation products. Asterisk denotes residual co-purifying
autophosphorylated CK2. (C) MS/MS analyses of in vitro phosphorylated N2-MUS81. Inset summarizes the identified phosphopeptides and residues.
were synchronized and S87 phosphorylation was deter-
mined. Phosphorylation was evaluated by IP/WB using the
anti-pS87MUS81 antibody from cells enriched in S-phase
after release from a double-thymidine block or in mito-
sis using Nocodazole (Noc; Figure 2A). Although MUS81
was found phosphorylated at S87 already in asynchronous
cells, the level of phosphorylation was substantially reduced
in S-phase enriched cells, but it was increased in mitotic
cells (Figure 2B). To evaluate phosphorylation in a more
physiological context, we performed anti-pS87MUS81 im-
munofluorescence in asynchronous cultures exposed to a
short EdU pulse to label S-phase cells or, as a control, in
Noc-arrested cultures. Dual EdU/pS87MUS81 immunos-
taining revealed that CK2-dependent phosphorylation is
absent in S-phase cells, while it is easily detected after Noc
treatment (Figure 2C).
Although the most relevant function of theMUS81 com-
plex is the resolution of recombination intermediates in late
G2/M, it may also process perturbed or collapsed replica-
tion forks (1). Thus, we analysed if phosphorylation of S87
might be a common readout of the MUS81 complex ac-
tivation. To this end, we treated HEK293TshMUS81 cells
expressing the wild-type FLAG-MUS81 protein with two
doses of aphidicolin (Aph), which partially arrest replica-
tion or perturb common fragile sites (CFS), or with hy-
droxyurea (HU). Phosphorylation was then assessed in
anti-FLAG IP by WB using the anti-pS87MUS81 anti-
body. All these treatments have been reported to stimulate
the function of both the MUS81 complexes, however, pro-
longed treatment with HU leads to a complete arrest of
S-phase progression and formation of MUS81-dependent
DSBs (8,12,13,36). Consistently, Aph treatment accumu-
lated cells in S-phase but did not completely arrest cell cycle
progression, while 24 h of HU blocked cells in G1/S phase
(Supplementary Figure S5). As expected, phosphorylation
of S87 was increased in Noc-treated cells, but it was also
stimulated by Aph treatments (Figure 2D). In contrast, and
despite the reported formation of DSBs by MUS81, phos-
phorylation of S87was barely detectable in cells treatedwith
HU (Figure 2D). To confirm that treatment with Aph stim-
ulated phosphorylation of MUS81 at S87, we performed
anti-pS87MUS81/EdU immunofluorescence in shMUS81
cells complemented with the wild-type form of MUS81
(Figure 2E). Treatment with a low-dose Aph increased the
number of nuclei positive to anti-pS87MUS81 immunos-
taining and the large majority of cells staining positive for
pS87 were EdU-negative. This indicates that a mild repli-
cation stress induces a CK2-dependent phosphorylation of
MUS81 most likely in G2/M phase.
Although it is widely accepted that the MUS81 com-
plex carries out its primary function in late G2 and mito-
sis, it is still unclear if it is active throughout all this pe-
riod. Our data suggest that phosphorylation at S87 can be
used as diagnostic sign ofMUS81 complex function.Hence,
we performed immunofluorescence to followMUS81 mod-
ification over time after release from a G2-arrest induced
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Figure 2. Phosphorylation of MUS81 on S87 is cell cycle-dependent and confined in early mitosis. (A) Flow cytometry analysis of HEK293T shMUS81
cells transiently expressing the wild-type form of FLAG-MUS81 after synchronization in S-phase (Thy+2h rec) or in mitosis (Noc). (B) After transient
transfection, FLAG-MUS81wt was immunoprecipitated from asynchronous (asynchr), S-phase orM-phase synchronized HEK293T shMUS81. Phospho-
rylation was analyzed byWB by using the anti-pS87MUS81 antibody, and the anti-pS87MUS81 signal was expressed as normalized percentage of the total
immunoprecipitatedMUS81. EV= Empty Vector (C) Anti-pS87MUS81 immunofluorescence staining (red) was performed inMRC5SV40 shMUS81 and
FLAG-MUS81wt stably complemented cells previously exposed to short EdU pulse to mark S-phase cells (green). Nuclei were depicted by DAPI staining
(blue). (D) After transient transfection, FLAG-MUS81wt was immunoprecipitated from asynchronous HEK293T shMUS81 cells treated as indicated.
anti-pS87MUS81 signal was expressed as normalized percentage of the total immunoprecipitated MUS81. EV = Empty Vector. (E) Immunofluorescence
experiments were performed to detect S87MUS81-phosphorylation uponmild replication stress induced by low dose of Aphidicolin.MRC5 shMUS81 cells
complemented with MUS81wt were exposed to short EdU pulse and then stained with anti-pS87 antibody (red) and DAPI (blue). Representative images
were shown. (F) Experimental scheme used to study S87MUS81 phosphorylation over time, fromG2-phase arrested cells to late mitosis. MRC5 shMUS81
cells complemented with MUS81wt were arrested in G2-phase by treatment with CDKi (RO-3306). Cells were immunostained for anti-pS87MUS81 at in-
dicated post-release time points. (G) Representative images of anti-pS87MUS81 immunostaining (red). The mean percentage of pS87MUS81 positive cells
is indicated in the images ± SE. At least 200 anaphase, 100 metaphase and 50 prophase cells were analysed in three replicates. Arrowheads indicate the
positive cells enlarged in the insets. (H) Representative images of anti-pS87 MUS81 antibody (red) co-localization with  -Tubulin antibody (green) in
metaphase cells. Nuclei were depicted with DAPI.
by CDK1 inhibition (30), as outlined in the experimental
scheme (Figure 2F). Cells released in late G2/M were sub-
jected to anti-pS87MUS81 immunofluorescence at different
time-points. Cells blocked in late-G2 showed high levels of
pS87MUS81 immunostaining, which increased during the
early time-point after release in mitosis (Figure 2G). Anti-
pS87MUS81 nuclear staining declined thereafter in con-
comitance with appearance of metaphase cells, as evaluated
by DAPI staining (Figure 2G). Interestingly, pS87MUS81
nuclear immunostaining was always confined to cells with
morphological features of late G2/prophase, even at later
post-release time-points, when population was enriched of
metaphase and anaphase cells (30 and 45 min; Figure 2G).
Of note, in several late mitotic cells, pS87MUS81 immunos-
taining was apparently accumulated at centrosomal regions
(see 45 min) as indicated by anti- -tubulin co-staining (Fig-
ure 2H).
In human cells, MUS81 exists as an heteroduplex in as-
sociation with EME1 or EME2 (37). Although there are
conflicting results about the cell cycle-dependent associa-
tionwith EME2 (18,20), EME1 is found throughout the cell
cycle, even if its function predominates in G2/M (20). Since
phosphorylation of S87 is stimulated in early mitosis and
is absent in S-phase synchronized cells, we investigated if it
was confined to the MUS81/EME1 complex. To this end,
we transiently expressed FLAG-MUS81 and Myc-EME2
or Myc-EME1 in HEK293T cells, and immunopurified the
fraction of MUS81 associated with EME2 or EME1 by
anti-Myc immunoprecipitation. We analysed S87 MUS81
phosphorylation in asynchronous cells or in cells accumu-
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Figure 3. S87-MUS81 phosphorylation regulates SLX4 binding. (A) MUS81 was immunoprecipitated from asynchronous or M-phase synchronized cells
expressingMUS81wt or its phosphorylationmutants. The fraction of SLX4 associated toMUS81was normalized on the total immunoprecipitatedMUS81.
(B) Interaction of MUS81 and SLX4 was analysed by PLA in asynchronous, THY and NOC-synchronized cells. Representative images of PLA fields are
shown.MUS81-SLX4 interaction resulted in red nuclear dots. The mean percentage of PLA-positive cells is represented in the graph in (C). (D) Chromatin
fraction was prepared from cells expressing MUS81wt or its phosphorylation mutants, and treated as indicated. The presence of MUS81 and the indicated
proteins in chromatin was assessed by WB. Histone H3 was used as loading control protein. Blots are representative of two different biological replicates.
(E)MUS81 phosphorylation was evaluated by anti-pS87MUS81 immunofluorescence on cells transfected siCTRL or siSLX4 and accumulated inM-phase
with Noc. The WB shows actual depletion levels, and images are representative of IF. The dispersion graph shows quantification of pS87MUS81 antibody
signal intensities.
lated in M-phase with Noc. As shown in Supplementary
Figures S6, S87 MUS81 phosphorylation was detectable
in both the MUS81 complexes but with different levels. In
theMUS81/EME1 complex, S87MUS81 phosphorylation
was enhanced by nocodazole treatment by about 3-fold over
the basal level while, in the MUS81/EME2 complex phos-
phorylation was similar in asynchronous cells but did not
change after nocodazole treatment.
Collectively, these results demonstrate that CK2 phos-
phorylates MUS81 at S87 in early mitosis, and that this
phosphorylation is stimulated in the presence of mild repli-
cation stress. Furthermore, they suggest that phosphoryla-
tion of S87 is prevented in S-phase and mainly concerns the
MUS81/EME1 complex.
Phosphorylation of MUS81 at Serine 87 by CK2 regulates
binding to SLX4
Association of the MUS81 complex with SLX4 is essen-
tial for some of its function (32), and given that the SLX4-
binding region is close to S87, we askedwhether phosphory-
lation could influence this interaction. To this aim, we per-
formed co-immunoprecipitation experiments in shMUS81
cells complemented with the wild-type form of wild-type
MUS81 or each of the two phosphorylation mutants. Of
note, in our cell model, the level of SLX4 apparently de-
creased in Noc-treated cells (Figure 3A, input). This un-
expected decrease seems cell-line specific as it was not ob-
served in HEK293T cells (Supplementary Figure S4) and
may be correlated with proteosomal degradation as it can
be reduced by MG132 (data not shown). In asynchronous
wild-type or MUS81S87A cells, little SLX4 was found in
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a complex with MUS81 (Figure 3A, IP). However, a 2-
fold higher amount of SLX4 co-immunoprecipitated with
MUS81 in MUS81S87D cells (Figure 3A). In Noc-treated
cells, association of MUS81 with SLX4 was more affected
by loss of S87 phosphorylation. Indeed, the unphosphory-
lableMUS81mutant (MUS81S87A) co-immunoprecipitated
less SLX4 than the wild-type or the phosphomimic form
(MUS81S87D; Figure 3A). Interestingly, while the amount of
SLX4 associated with MUS81 was increased by Noc treat-
ment in wild-type cells, no modulation was detected in the
MUS81S87A or in the MUS81S87D mutant (Figure 3A). In
contrast, MUS81 immunoprecipitated similar amounts of
EME1 independently on the phosphorylation status of S87
(Figure 3A). To further confirm that phosphorylation of
S87 affected the interaction ofMUS81 with SLX4, we anal-
ysed protein-protein interaction at the single cell level by the
proximity-ligation assay (PLA). Interestingly, and consis-
tently with biochemical assays, association of MUS81 with
SLX4 was enhanced in MUS81S87D cells, while it was only
barely detectable in wild-type cells or in cells expressing the
unphosphorylable protein, as evaluated by the number of
PLA-positive cells (Figure 3B and C). Of note, association
of MUS81 with SLX4 is strongly enhanced in the presence
of the phosphomimic mutant (MUS81S87D) also in cells en-
riched in S-phase by a thymidine block (Figure 3B and C),
even if their association should be actively prevented at this
stage to avoid targeting of replication intermediates (18).
To test if enhanced association between MUS81 and SLX4
might correlate with an increased association with chro-
matin, we performed cellular fractionation experiments in
cells treated with Noc or exposed to HU for 24 h, a con-
dition in which we observed little if any S87 phosphoryla-
tion (Figure 2D).Western blotting analysis of the chromatin
fraction with an anti-MUS81 antibody showed no substan-
tial difference in the two phosphorylation mutants, as com-
pared to the wild-type (Figure 3D). In a similar way, the
fraction of chromatin-associated SLX4 did not vary among
the different MUS81 forms, however, the amount of EME1
in chromatin was substantially elevated in asynchronous
or Noc-arrested cells expressing the phosphomimetic mu-
tant (Figure 3D). In contrast, expression of the unphospho-
rylable MUS81 mutant enhanced the level of chromatin-
associated EME1 and EME2 in cells treated with 24h HU,
and also increased the amount of EME2 in asynchronous,
untreated, cells (Figure 3D).
As our results indicate that a mutation mimicking consti-
tutive S87 MUS81 phosphorylation stimulates association
with SLX4 but not chromatin recruitment, we decided to
analyse if this interaction might be required for subsequent
phosphorylation of MUS81 by CK2. Hence, we analysed
S87 phosphorylation by anti-pS87MUS81 IF in cells trans-
fected or not with siRNAs against SLX4 and accumulated
inmitosis withNoc. Depletion of SLX4 did not prevent S87
MUS81 phosphorylation, which is indistinguishable from
wild-type cells (Figure 3E).
Therefore, our data indicate that phosphorylation of
S87 by CK2 is important to stabilize or stimulate the
MUS81-SLX4 interaction. Moreover, they suggest that
phosphorylation takes place before formation of the
MUS81/EME1/SLX4 complex.
Phosphorylation status of MUS81 at S87 controls unsched-
uled targeting of HJ-like intermediates in S-phase
By regulating interaction with SLX4, phosphorylation of
MUS81 S87 by CK2 may have functional implications.
Hence, we used cells expressing the S87 MUS81 phospho-
mutants as a very specific tool to analyse the phenotypic
consequences of a deregulatedMUS81-EME1 function, by-
passing the need to interfere with cell-cycle kinases. Our
analysis of cell growth evidenced a substantial delay in
the proliferation of MUS81S87D cells, while cells express-
ing the related unphosphorylable MUS81 mutant did not
show any apparent defect as compared to the wild-type
(Figure 4A). Delayed proliferation rate of MUS81S87D cells
did not correlate with substantial cell cycle defects (Supple-
mentary Figure S7A). Thus, we analysed if it could derive
from accumulation of spontaneous DNA damage by doing
immunofluorescence against  -H2AX or 53BP1. MUS81
deficiency or expression of wild-type MUS81 resulted in
low level of  -H2AX-positive cells (<2%) (Figure 4B). Very
few nuclei were positive for  -H2AX also in MUS81S87A
cells, however, their number was increased of about 10-fold
in the phosphomimic S87D mutant (Figure 4 B). Inter-
estingly, in the S87D MUS81 mutant, almost the totality
of the  -H2AX-positive cells were also Cyclin A-positive
(i.e. in S or G2 phase) and the large part (60%) were in
S-phase (EdU-positive) (Figure 4C and D). Similarly, the
portion of 53BP1-foci/Cyclin A double-positive cells in the
population was increased by expression of the phospho-
mimicMUS81mutant as compared toMUS81S87A or wild-
type cells (Figure 4E). Flow cytometry analysis of the  -
H2AX-positive population confirmed that DNA damage
arises mostly in S-phase or in G2/M cells (Supplemen-
tary Figure S7 B). The higher load of DNA damage in
cells expressing the phosphomimic S87D MUS81 protein
prompted us to analyse if this could derive from unsched-
uled targeting of intermediates duringDNA replication.We
recently demonstrated that ectopic expression of a GFP-
RuvA fusion protein is sufficient to interfere with forma-
tion of DSBs by structure-specific endonucleases in human
cells during S-phase (38). Hence, we ectopically expressed
GFP-RuvA in wild-type or in MUS81S87D cells and anal-
ysed the presence of DNA damage by neutral Comet assay.
As shown in Figure 5A, the amount of spontaneous DSBs
detected in wild-type cells did not decrease upon expression
of RuvA. However, expression of RuvA significantly de-
creased the accumulation ofDSBs inMUS81S87D cells. Sim-
ilarly, when we analysed the formation of 53BP1 foci after
ectopic RuvA expression, we observed a substantial reduc-
tion of the 53BP1 focus-forming activity especially in cells
expressing the S87DMUS81 mutant (Figure 5B and C). To
determine if the incidental cleavage of HJ-like intermedi-
ates triggered by deregulated phosphorylation ofMUS81 at
S87 might correlate also with increased enzymatic activity,
we immunopurified FLAG-MUS81 complexes from cells
transiently over-expressing the wild-type form of MUS81
or its phosphorylation mutants and assessed the associ-
ated endonuclease activity after incubation of anti-FLAG
immunoprecipitates with a model nicked HJ, one of the
preferred in vitro MUS81 substrates (Supplementary Fig-
ure S8A). As shown in Supplementary Figure S8B, wild
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Figure 4. Constitutive phosphorylation of MUS81 at S87 affects cell growth and induces DNA damage. (A) Growth curve in shMUS81 cells stably ex-
pressing the wild-type form of MUS81 and it S87 phosphorylation mutants. Each point represents the average number of counts from two independent
experiments. (B) Accumulation of spontaneous damage inMUS81 phosphorylationmutants. Untreated cells were immunostained with  -H2AX antibody,
the graph represents the analysis of  -H2AXpositive cells. Representative images of fluorescence fields are shown ( -H2AX antibody: green; nuclear DNA:
blue). (C) DNA damage, in S/G2-phase cells, was detected by double IF using anti-Cyclin A and  -H2AX antibodies. (D) Analysis of the level of DNA
damage during replication. Cells in S-phase were labelled by an EdU pulse and the graph shows the percentage of EdU (green) and anti- -H2AX (red)
positive cells. Nuclear DNA was counterstained by DAPI (blue). (E) Analysis of 53BP1 foci formation in Cyclin A positive cells. Representative image of
fluorescence cells stained with anti-53BP1 (green) and anti-Cyclin A (red) antibodies. Nuclear DNA was counterstained by DAPI. The graph shows quan-
tification of the 53BP1-positive Cyclin A-cells. Data are mean values from three independent experiments. Statistical analysis was performed by Student’s
t-test. Significance is reported compared to the wild-type: ***P < 0.01; *P < 0.05.
type MUS81 apparently cleaved the substrate with com-
parable efficiency between asynchronous and M-phase en-
riched cells, while the MUS81-S87D mutant seemed to in-
crease its activity in nocodazole-treated cells. In contrast,
the unphosphorylable MUS81 mutant showed always very
little activity. Of note, and in agreement with our PLA and
the CoIP data (see Figure 3), less SLX4 was found associ-
ated with the unphosphorylable MUS81 mutant (Supple-
mentary Figure S8C). Surprisingly, loss of S87 phospho-
rylation MUS81 increased the ability of the protein to im-
munoprecipitate EME2 although the amount of EME1was
unchanged.
Collectively our findings indicate that deregulated
MUS81 phosphorylation at S87 and subsequent MUS81-
EME1-SLX4 association is sufficient to induce DNA
damage in S-phase because of incidental cleavage of HJ-
like intermediates, which is not correlated with enhanced
enzymatic activity.
Phosphorylation at Serine 87 induces prematuremitotic entry
through unscheduled MUS81 function in S-phase
Recent data evidenced that inhibition of WEE1 leads to
premature activation of the MUS81 complex, because it re-
leases CDK1 inhibition and stimulates phosphorylation of
SLX4, licensing the formation of the MUS81/SLX4 com-
plex in S-phase, and inducing uncontrolled progression in
mitosis of unreplicated cells (18). We show that phosphory-
lation of MUS81 at S87 is crucial to MUS81-EME1 activa-
tion. Hence, we analysed if abrogation of S87 phosphoryla-
tion could revert the effect of WEE1 inhibition. To analyse
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Figure 5. Ectopic GFP-RuvA expression reduces formation of DSBs and 53BP1 foci in constitutive-active MUS81 mutant. (A) MRC5 shMUS81 cells,
stably expressing WT or S87D phosphomimetic MUS81 were transfected or not with GFP-RuvA. DSBs were evaluated 48h after transfection by neutral
Comet assay. (B) The presence of 53BP1 nuclear foci was evaluated by IF 48 h after transfection. The graph shows the fold increase of 53BP1 foci-positive
cells over the untransfected cells. Data are presented as mean± standard error (SE) from three independent experiments. *P≤ 0.5; ****P≤ 0.001, ANOVA
test. (C) Representative microscopy fields are presented: 53BP1 antibody (green or red), GFP-RuvA and nuclear DNAwas counterstained by DAPI (blue).
premature mitotic entry from S-phase, we pulse-labelled a
subset of replicating cells with BrdU, chased them in BrdU-
free medium in the presence or absence of WEE1 inhibitor,
and analysed progression of the BrdU-positive population
through the cell cycle by bivariate flow cytometry (Figure
6A). Under unchallenged conditions, no substantial dif-
ference in the progression of the labelled S-phase popula-
tion was observed in wild-type and MUS81S87A cells. How-
ever, a higher percentage of BrdU-labeled G1 cells (G1*),
a sign of a faster transit through the cell cycle, was ob-
served in MUS81S87D cells after 5 h of chase as compared
with the wild-type ones (Figure 6B and C). As expected,
in wild-type cells, inhibition of WEE1 (WEE1i) resulted in
a faster progression from S-phase to mitosis, resulting in a
strong increase of BrdU-positive cells in the subsequentG1-
phase. In contrast, and interestingly, expression of the un-
phosphorylable S87A-MUS81 protein completely reverted
the effect of WEE1i on cell cycle. Surprisingly, a reduc-
tion of the number of BrdU-positive G1 cells after WEE1
inhibition was also observed in cells expressing the phos-
phomimetic S87D-MUS81 mutant. Consistent results were
also obtained by analysing progression of a BrdU-pulse la-
belled population to mitosis by anti-pS10H3/BrdU dou-
ble immunofluorescence (Figure 6D). Indeed, treatment of
wild-type cells with WEE1i greatly increased the number of
BrdU-positive cells accumulated in mitosis by Noc, while
expression of the S87A-MUS81 mutant reverted the phe-
notype. Of note, inhibition of WEE1 failed to increase the
fraction of BrdU-positive mitosis detected in MUS81S87D
cells. Inhibition of CDK1 can prevent unscheduled activa-
tion of MUS81 by WEE1i (18). As shown in Supplemen-
tary Figure S9 A, inhibition of CDK1 reverted the progres-
sion of BrdU-labelled S-phase cells to G2/M and the sub-
sequent G1, which is stimulated by WEE1 inhibition, irre-
spective of the presence of a mutant MUS81 protein. Sup-
pression of the WEE1i-induced premature mitotic entry is
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Figure 6. Premature mitotic entry mediated by unscheduled MUS81 function in S-phase depends on phosphorylation at S87. (A) Experimental workflow.
(B) S-phase cells were pulse-labelled with BrdU and released in free medium for 5 h, in the presence or not of the WEE1 inhibitor MK-1775 (WEE1i).
Progression of S-phase cells through the cell cycle was analysed by bivariate flow cytometry. The scheme indicates how each population was assigned.
The star (*) denotes S-labeled, BrdU-positive, populations. Density plots depict mean BrdU intensities versus total nuclear DNA intensities (PI). The
percentage of cells found in each phase of cell cycle is indicated. (C) The graph shows the percentage of cells in G2/M*, S* and G1* phase treated or not
with WEE1i inhibitor MK-1775, relative to scatterplots in (B). (D) Immunofluorescence analysis of S-M progression. S-phase cells were labelled with a 1 h
BrdU pulse, and released in nocodazole to accumulate mitosis. Cells accumulated in mitosis for 16 h, in presence or not of WEE1i, and immunostained
using anti-BrdU and pS10H3 antibodies. Data are presented as mean ± standard error (SE) from three independent experiments. **P < 0.1; ns = not
significant, ANOVA test.
also obtained with EME2 or SLX4 depletion (18). In wild-
type cells, depletion of EME2 reduced the unscheduled pro-
gression from S to G2/M and G1, which is stimulated by
WEE1 inhibition, but only partially (Supplementary Fig-
ure S9B and C). Of note, depletion of EME2 reduced the
limited progression from S toG2/MandG1 observed in the
S87A-MUS81 mutant, while was largely ineffective in mod-
ulating the phenotype of the S87D-MUS81 mutant, either
in the absence or in the presence of WEE1i. A consistent ef-
fect was observed when we analysed the S-M progression
by anti-pS10H3/BrdU double immunofluorescence (Sup-
plementary Figure S9D). Depletion of EME2 reduced the
premature S-M transit induced byWEE1i in wild-type cells,
while it minimally affects theMUS81S87D phenotype. As ex-
pected, depletion of SLX4 completely reverts premature S-
M transit independently on the deregulated S87 phospho-
rylation of MUS81 (Supplementary Figure S9D).
These results indicate that phosphorylation ofMUS81 by
CK2 is absolutely required for the pathological S/M transit
associated to WEE1 inhibition and deregulated phospho-
rylation of SLX4. Moreover, they suggest that the presence
of a constitutively-active MUS81 complex and WEE1 inhi-
bition does not synergize, but rather result in an apparent
slow-down of the cell cycle.
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Figure 7. Regulated phosphorylation of MUS81 at S87 is essential to prevent accumulation of genome instability. (A) Analysis of the bulky anaphases
bridges inMUS81 phosphomutants treated with a low-dose Aphidicolin (Aph). The graph shows the fractions of mitotic cells with bulky anaphase bridges.
Error bars indicate SE; n= 3 (>50mitotic cells were analyzed in each population).Data are presented asmean± standard error (SE) from three independent
experiments. *P< 0.5; **P< 0.1; ***P<0.01, ANOVA test. Significance is reported compared to the wild-type. Representative images of single anaphases
from the phosphomimetic MUS81 mutant are shown. Arrows indicate bridges. (B) Experimental scheme for evaluation of chromosomal aberrations is
shown. Dot plot shows the number of chromosome aberrations per cell. Data are presented as means of three independent experiments. Horizontal black
lines represent the mean ± SE. (ns, not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001 two-tailed Student’s t test). Representative Giemsa-stained
metaphases are given. Arrows in red indicate chromosomal aberrations. (C) Analysis of the frequency of metaphase spreads with chromatid exchanges in
cells treated and processed as in (B). Bar graph shows the percentage of chromatid exchanges per metaphase cell. Data are presented as means of three
independent experiments. Horizontal black lines represent the mean ± SE. A representative Giemsa-stained metaphase with chromatid exchanges is given.
(D) Experimental scheme for evaluation of chromosomal aberrations is shown. Bar graph shows the frequency of pulverizedmetaphases permetaphase cell.
Data are presented as means of three independent experiments. Error bars representing standard errors are not shown or clarity but are <15 of the mean
(*P < 0.5; **P < 0.01; ***P < 0.001; two-tailed Student’s t test). Representative Giemsa-stained metaphases are given for both normal and pulverized
phenotype. Significance is reported compared to the wild-type.
Regulated phosphorylation of MUS81 at Serine 87 is essen-
tial to prevent accumulation of genome instability
Downregulation of MUS81 induces mitotic defects and ac-
cumulation of bulky anaphase bridges as a consequence of
poor resolution of replication/recombination intermediates
prior tomitosis (19,39). Our data suggest that S87 phospho-
rylation of MUS81 may affect function of the complex in
mitosis. Hence, we analysed the presence of bulky anaphase
bridges in cells expressing the wild-type MUS81 or the two
S87 phosphomutants, exposed or not to a low-dose Aph
(Figure 7A). Under unperturbed cell growth, the number
of anaphase cells with bulky chromatin bridges was found
elevated, albeit modestly, in bothMUS81-depleted cells and
in cells expressing the unphosphorylable S87A-MUS81 pro-
tein. In contrast, very few anaphases with bulky chromatin
bridges were found in cells expressing the phosphomimic
mutant of MUS81. In Aph-treated cells, the percentage of
anaphases with bulky chromatin bridges was similar among
cell lines, except those expressing the phosphomimic S87D-
MUS81mutant, which showed less anaphase bridges. These
data support the functional role of S87 phosphorylation of
MUS81 in mitosis. Nevertheless, deregulation of S87 phos-
phorylation causes DNA damage in S-phase being involved
in premature formation of the MUS81/EME1/SLX4 com-
plex. Hence, we investigated whether expression of the S87
unphosphorylable or phosphomimicMUS81mutant might
undermine genome integrity. To this end, we analysed the
number and type of chromosomal damage in metaphase
spreads from cells treated or not with a low-dose Aph,
which induces a mild replication stress that the MUS81
complex contributes to fix. As shown in Figure 7B, mild
replication stress increased the frequency of chromosome
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breakage in wild-type cells. As expected, the number of
chromosome breaks detected on mild replication stress was
slightly reduced uponMUS81 downregulation while, unex-
pectedly, it was only slightly enhanced by expression of the
S87 unphosphorylableMUS81mutant. In contrast, the fre-
quency of chromosome breakage was significantly higher
in cells expressing the S87D-MUS81 mutant already under
unperturbed replication and increased further upon treat-
ment with Aph. Interestingly, MUS81S87D cells also showed
complex chromosome aberrations, such as chromatid ex-
changes and pulverized metaphases, which were otherwise
absent in wild-type or MUS81S87A cells (Figure 7C). The
unscheduled targeting of replication forks by the MUS81
endonuclease triggered by chemical inhibition of WEE1 is
sufficient to induce chromosome pulverization (18). As we
show that S87 phosphorylation predominates onWEE1 in-
hibition (Figure 6), we evaluated if chromosome pulveriza-
tion observed in cells treatedwith theWEE1imight bemod-
ulated by the presence of the two S87 phosphomutants of
MUS81. As reported in Figure 7D, inhibition of WEE1 re-
sulted in the appearance of pulverized metaphases in wild-
type cells, and this phenotype greatly increased in response
to Aph. As expected, the percentage of pulverisation was
significantly reduced inMUS81-depleted cells respect to the
wild-type, especially after Aph treatment (Figure 7D). In-
terestingly, WEE1i-dependent chromosome pulverisation
was suppressed also by expression of the S87A-MUS81
mutant (Figure 7D). Conversely, MUS81S87D cells showed
chromosome pulverization even in absence of WEE1i, and
the phenotype was significantly enhanced in its presence,
suggesting that pharmacological override of cell cycle con-
trol and unscheduled targeting of replication forks by the
MUS81/EME1 complex act synergistically. Interestingly,
while depletion of EME2 partially rescued the pulveriza-
tion phenotype associated to inhibition of WEE1 in wild-
type cells it failed to modulate the pulverisation detected
in MUS81S87D cells (Supplementary Figure S10A and B),
confirming that expression of the phosphomimetic MUS81
mutant preferentially engages theMUS81/EME1 complex.
Therefore, we conclude that phosphorylation of MUS81
S87 by CK2 is required to support function of the MUS81
complex during resolution of intermediates accumulating
under mild replication stress, but also that loss of regulated
phosphorylation strongly undermines genome integrity.
DISCUSSION
The structure-specific endonuclease MUS81/EME1 plays
important roles in the resolution of recombination inter-
mediates, however, its function needs to be carefully regu-
lated to avoid an unscheduled targeting intermediates dur-
ing DNA replication, which may result in genome insta-
bility. Regulation of the MUS81 complex has been mostly
investigated in yeast, and several publications demon-
strated that cell cycle-dependent phosphorylation of the
Mms4EME1 subunit by Cdc28CDK1 or Cdc5PLK1 ensures
activation of the MUS81 complex in G2/M (16,40,41).
In yeast, the MUS81 complex can be also regulated by
checkpoint kinases in response to DNA damage (16,17).
In human cells, a cell cycle-dependent regulation of the
MUS81 complex has been indirectly inferred from associ-
ation with PLK1, and the presence of phosphorylated iso-
forms of EME1 in mitosis (42,43). The functional role of
such events and the identity of the targeted residues are
almost unknown, and only recently a mechanistic link be-
tween CDK1-dependent phosphorylation and activation of
the human SLX4-MUS81-EME2 axis has been revealed
(18). However, in most cases, the phenotype associated with
loss of MUS81 complex regulation has been deducted from
inhibition of cell cycle-related kinases, such as CDK1 or
PLK1, so that the observed effect may derive also from per-
turbation of cell cycle progression per se or from altered
function of other targets.
Here, we find that the biological function of the MUS81-
EME1 complex in human cells is positively regulated by
CK2, which phosphorylates Serine 87 (S87) of the MUS81
subunit in mitosis. Interestingly, phosphorylation at S87 in-
creases from late G2 to prophase and disappears as soon
as cells proceed to metaphase. Activation of the MUS81-
EME1 complex during prophase or pro-metaphase has
been hypothesised from interaction with its key partners
using synchronised cells (18). Our data on S87 phospho-
rylation confirm that the human MUS81-EME1 complex
becomes active in late G2 and early mitosis and suggest
that pS87MUS81 is excluded from chromatin inmetaphase.
Our findings also show that MUS81 S87 phosphorylation
is very low or undetectable in S-phase. The MUS81 com-
plex(es) needs to be switched off during normal replication
(4), and downregulation of S87 phosphorylation is consis-
tent with the need to avoid adventitious targeting of repli-
cation intermediates. Although MUS81 can form distinct
heterodimeric complexes with EME1 or EME2 (20), our
data show that phosphorylation of S87 is mainly detected
in the MUS81-EME1 complex. This is consistent with the
MUS81-EME1 dimer being active in mitosis and suggests
that different phosphorylation eventsmay be involved in the
regulation of specific MUS81 complexes. From this point
of view, phosphorylation of the invariant subunit of the
MUS81 heterodimers could be advantageous to direct as-
sociation of MUS81 with EME1 or EME2, and to mod-
ulate endonucleolytic cleavage in vivo. From this point of
view, although the amount of MUS81 in chromatin is un-
changed by the S87 phosphorylation status, the different
level of chromatin-associated EME1 or EME2 in the S87
phosphorylation mutants of MUS81 may reflect the ability
to form different complexes.
Experiments using inhibitors of cell cycle kinases pro-
vided clues about consequences of unscheduled activation
of theMUS81 complex on viability and chromosome stabil-
ity in human cells (18,19,33). Our findings clearly demon-
strate that expression of a phosphomimic S87D-MUS81
mutant is detrimental to cell proliferation because of the
generation of DSBs in S-phase cells. Interestingly, such un-
scheduled formation of DSBs in S-phase is largely pre-
vented by ectopic expression of the bacterial RuvA pro-
tein. RuvA is a Holliday junction-binding protein, and its
ectopic expression in human cells counteracts generation
of DSBs by another structure-specific endonuclease, GEN1
(38). Hence, from a mechanistic point of view, a mutation
mimicking constitutive phosphorylation of MUS81 at S87
is sufficient to unleash targeting of HJ-like intermediates
arising during normal replication and this is linked to gener-
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ation of DNA damage. Much more interestingly, under un-
perturbed cell growth, expression of the S87D-MUS81 mu-
tant results in a chromosome fragility phenotype, which is
more marked than that observed in cells expressing the un-
phosphorylable S87A-MUS81 form. In addition, cells ex-
pressing the phosphomimic S87D-MUS81 mutant not only
have elevated number of chromosome breaks and gaps, but
also have a striking accumulation of radial chromosomes.
Since the presence of radial chromosomes is associated with
repair of DSBs at collapsed forks by NHEJ (44), unsched-
uled formation of DSBs by MUS81 complex in S-phase
may engage end-joining repair in addition to homologous
recombination, which may promote gross chromosomal re-
arrangements.
In unperturbed cells, loss of the MUS81 complex func-
tion results in mitotic defects including accumulation of
bulky anaphase bridges (19,39). We show that cells express-
ing the S87A-MUS81 mutant recapitulate the high num-
ber of bulky anaphase bridges observed in cells depleted
of MUS81, although they show few chromosome-breaks
in metaphase. In contrast, expression of the phosphomimic
S87D-MUS81 results in few bulky anaphase bridges, but in
a striking chromosome fragility. Hence, formation of DSBs
by an unscheduled function of the MUS81 complex during
a normal S-phase is expected to be much more detrimental
to genome stability of that associated with activation of the
MUS81 complex at collapsed replication forks, while loss of
resolution activity in early mitosis is better sustained, prob-
ably because of backup activities (7,9,11).
Prolonged or pathological replication fork arrest has
been associated to induction of MUS81-dependent DSBs
(7,8,11,45). Our data show that MUS81 S87 phosphoryla-
tion is low in cells treated with HU for 24 h, a condition
known to promoteMUS81 function at collapsed replication
forks (8), indicating distinct regulatory mechanisms of the
human MUS81 complex during mild or persisting replica-
tion stress. However, we also provide evidence that CK2 in-
hibition reverts formation of MUS81-dependent DSBs af-
terHU treatment. Hence, CK2-dependent phosphorylation
on other residues ofMUS81 or EME1/2may be involved in
regulating the MUS81 complex under different conditions,
as reported in yeast (16,17). Alternatively, CK2 may target
other proteins required for MUS81 complex function un-
der conditions of persisting replication stress. Interestingly,
CK2 phosphorylates, among others, the RAD51 recombi-
nase (25). Of note, RAD51 or RAD52 are involved in the
formation of the MUS81 complex substrates at demised
replication forks (7,45). Clarifying this interesting point
clearly goes beyond the scope of this work and deserves fu-
ture investigations.
In contrast to persisting or pathological replication stress,
a mild condition of replication perturbation that does not
arrest cells in S-phase can stimulate S87 phosphorylation
of MUS81. Such mild condition of replication stress has
been reported to trigger the function of the MUS81-EME1
complex to resolve intermediates at under-replicated re-
gions, such as common fragile sites (12,13). Our data on the
cell cycle-specificity of MUS81 S87 phosphorylation sug-
gest that this function of the MUS81 complex occurs post-
replication or in mitosis when common fragile sites loci
might conclude their replication (30). Strikingly, expression
of the unphosphorylable MUS81 S87A mutant enhances
chromosomal damage in cells treated with low-dose Aph
only slightly, while the presence of a phosphomimicMUS81
mutant dramatically increases the amount of chromosome
breakage and radial chromosomes after a mild replication
stress.
Hence, as in untreated cells, the phenotype deriving from
unscheduled targeting of perturbed replication forks by the
MUS81 complex predominates over that resulting from loss
of function in G2/M.
Our experiments indicate that phosphorylation of
MUS81 S87 is important to establish a correct interaction
between MUS81 and SLX4. SLX4 is a versatile scaffold
involved in recruitment of multiple endonucleases (43,46).
In particular, activation of MUS81/EME1 in mitotic cells
requires association with SLX4 through a region localized
in the first 90 aminoacids of MUS81 (18,34,42). Interest-
ingly, deletion of the SLX4-interacting region of MUS81
broadens substrate specificity, allowing the complex to
target much more easily also replication intermediates
at perturbed forks (47). Serine 87 is within the region
interacting with SLX4 and its phosphorylation makes
MUS81 more prone to associate with SLX4, providing a
mechanistic explanation to the unscheduled targeting by
the MUS81 S87D protein of HJ-like and possibly other
branched intermediates during replication.
It has been recently reported that inhibition of WEE1 li-
cences association of MUS81/EME2 with SLX4 resulting
in a wide chromosome instability in the form of pulver-
ized metaphases (18). Interestingly, the dramatic effect of
WEE1 inhibition on premature cell cycle progression and
chromosome pulverization is completely prevented by the
unphosphorylable MUS81 S87A mutant, reinforcing the
strong functional value of S87 phosphorylation. In our ex-
perimental conditions, however, depletion of EME2 sub-
stantially reduces but does not suppress WEE1i-associated
phenotypes. In particular, expression of the S87D-MUS81
mutant induces a phenotype that is only minimally affected
by EME2 depletion. As S87 phosphorylation occurs mainly
in theMUS81/EME1 complex, it is conceivable that expres-
sion of the phosphomimic protein favours engagement of
the MUS81/EME1 complex while, in wild-type cells, both
complexes might contribute to the WEE1i-dependent phe-
notypes. Alternatively, the relative amount of each MUS81
complex may be cell-specific and affect also the genetic de-
pendency of the WEE1i-dependent effects. Moreover, as
WEE1-mediated promotion of MUS81/SLX4 interaction
involves CDK1-dependent phosphorylation of SLX4 (18),
our data indicate that both the partners must bemodified to
promote a productive interaction. CK2 is a crucial kinase in
mitosis, and is positively regulated byCDK1 (22). From this
point of view, human cells might have evolved a redundant
regulatory mechanism to restrain MUS81 complex activity
in late G2 and M phase. Indeed, elevated CDK1 level may
directly contribute to activate the MUS81 complex phos-
phorylating EME1 (2), while, indirectly, may enhance ac-
tivity of CK2 that, in turn, targets MUS81 licensing inter-
action with an already phosphorylated SLX4 (Figure 8).
This elaborate regulatory mechanism will allow cleavage of
branched DNA intermediates during a narrow window at
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Figure 8. Summarizing model to illustrate the contribution of CK2-dependent phosphorylation to the MUS81/EME1/SLX4 regulation.
the beginning of mitosis, contributing to limit chromosome
instability.
Our results may also have strong implications for the on-
set of genome instability in cancer. Indeed, CK2 has been
found overexpressed in many human tumours (48). Hence,
it is tempting to speculate that in CK2-overexpressing can-
cer cells also the biological function ofMUS81/EME1may
be elevated and contribute strongly to genome instability
and, possibly, aggressiveness. Further studies will be needed
to evaluate the status of MUS81 S87 in human tumours to-
gether with level and type of genome instability, in order to
see if there is any correlation with the expression of CK2.
Altogether, our study provides the first mechanistic in-
sight into the regulation of the human MUS81 complex,
with functional implications on the consequences of dereg-
ulated processing of replication intermediates during unper-
turbed or minimally-perturbed DNA replication.
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